**Table E1:** Summary of adverse events occurring during one year of treatment with mepolizumab

|  |  |
| --- | --- |
| **Adverse Events**  | **Number & % AE** |
| **Bruising**  | 1 (5.3%)  |
| **Chalazion**  | 1 (5.3%)  |
| **Conjunctivitis**  | 1 (5.3%)  |
| **Dizziness**  | 4 (21.0%)  |
| **Hair loss**  | 1 (5.3%)  |
| **Fatigue**  | 1 (5.3%)  |
| **Headache**  | 3 (15.8%)  |
| **Itching**  | 1 (5.3%)  |
| **Local injection site reactions**  | 1 (5.3%)  |
| **Musculoskeletal pain**  | 3 (15.8%)  |
| **Otitis media**  | 1 (5.3%)  |
| **Productive cough**  | 1 (5.3%)  |
| **Rhinitis-Nasal congestion**  | 5 (26.3%)  |
| **Upper respiratory tract infection**  | 5 (26.3%)  |
| **Urinary tract infection**  | 1 (5.3%)  |